Advertisement

Fascioliasis

  • Santiago Mas-ComaEmail author
  • Mª Adela Valero
  • Mª Dolores Bargues
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1154)

Abstract

Fascioliasis is a major parasitic disease caused by the digenetic trematodes Fasciola hepatica and Fasciola gigantica. The disease is a well-known veterinary problem of worldwide distribution. Fascioliasis is the vector-borne parasitic disease presenting the widest latitudinal, longitudinal, and altitudinal distribution known at present. In the last two decades, many surveys have shown it to be an important public health problem as well, including estimations of 2.4 million, up to 17 million people, or even higher depending on the hitherto unknown situations mainly in several regions of Asia and Africa. In recent years, the increasing number of human case reports in many countries of the five continents and the results of studies on pathogenicity and immunity, mainly regarding the chronic period of the disease, were the reasons why it was decided to no longer consider fascioliasis merely a secondary zoonotic disease but an important human parasitic disease. In this chapter, we review the most relevant features in relation to fascioliasis, including from the most traditional to the most innovative aspects.

Keywords

Trematode Zoonoses Fascioliasis Fasciola hepatica Fasciola gigantica Food-borne trematode 

Notes

Acknowledgements

Reviews of fascioliasis carried out within Projects SAF2010-20805 of the Ministry of Economy and Competitiveness, Madrid, Spain; by Health Research Project No. PI16/00520, Subprograma Estatal de Generación de Conocimiento de la Acción Estratégica en Salud (AES), Plan Estatal de Investigación Científica y Técnica y de Innovación, ISCIII-MINECO, Madrid, Spain; by Project No. 2017/ACDE/001583 de Innovación para el Desarrollo of the Agencia Española de Cooperación Internacional para el Desarrollo (AECID), Ministry of Foreign Affairs and Cooperation, Madrid, Spain; by the Red de Investigación de Centros de Enfermedades Tropicales – RICET (Project No. RD16/0027/0023 of the PN de I + D + I, ISCIII-Subdirección General de Redes y Centros de Investigación Cooperativa RETICS), Ministry of Health and Consumption, Madrid; by Project No. 2016/099 of the PROMETEO Program, Programa of Ayudas para Grupos de Investigación de Excelencia, Generalitat Valenciana, Valencia, Spain.

References

  1. Afshan K, Valero MA, Qayyum M, Peixoto RV, Magraner A, Mas-Coma S (2014a) Phenotypes of intermediate forms of Fasciola and Fasciola gigantica in buffaloes from Central Punjab, Pakistan. J Helminthol 88:417–426PubMedCrossRefGoogle Scholar
  2. Afshan K, Fortes-Lima CA, Artigas P, Valero AM, Qayyum M, Mas-Coma S (2014b) Impact of climate change and man-made irrigation systems on the transmission risk, long-term trend and seasonality of human and animal fascioliasis in Pakistan. Geospat Health 8:317–334PubMedCrossRefGoogle Scholar
  3. Agnamey P, Fortes-Lopes E, Raccurt CP, Boncy J, Totet A (2012) Cross-sectional serological survey of human fascioliasis in Haiti. J Parasitol Res 2012:751951PubMedCrossRefGoogle Scholar
  4. Ahasan SA, Valero MA, Chowdhury EH, Islam MT, Islam MR, Hussain MMM, Peixoto RV, Berinde L, Panova M, Mas-Coma S (2016) CIAS detection of Fasciola hepatica/F. gigantica intermediate forms in bovines from Bangladesh. Acta Parasitol 61:267–277PubMedCrossRefGoogle Scholar
  5. Ai L, Dong SJ, Zhang WY, Elsheikha HM, Mahmmod YS, Lin RQ, Yuan ZG, Shi YL, Huang WY, Zhu XQ (2010) Specific PCR-based assays for the identification of Fasciola species: their development, evaluation and potential usefulness in prevalence surveys. Ann Trop Med Parasitol 104:65–72PubMedCrossRefGoogle Scholar
  6. Alasaad S, Soriguer RC, Abu-Madi M, El Behairy A, Jowers MJ, Baños PD, Píriz A, Fickel J, Zhu XQ (2011) A TaqMan real-time PCR-based assay for the identification of Fasciola spp. Vet Parasitol 179:266–271PubMedCrossRefGoogle Scholar
  7. Anonymous (1988) Parasitic diseases: hepatic distomiasis caused by Fasciola hepatica. Wkly Epidemiol Rec 63:109–111Google Scholar
  8. Apt W, Aguilera X, Vega F, Alacaíno H, Zulantay I, Apt P, González G, Retamal C, Rodríguez J, Sandoval J (1993) Prevalencia de fascioliasis en humanos, caballos, cerdos y conejos silvestres en tres provincias de Chile. Boletín de la Oficina Sanitaria de Panamá 115:405–414Google Scholar
  9. Apt W, Aguilera X, Vega F, Pérez C, Gabor M, Apt P (1995) Treatment of human chronic fascioliasis with triclabendazol: drug efficacy and serologic response. Am J Trop Med Hyg 52:532–535PubMedCrossRefGoogle Scholar
  10. Arenas R, Espinoza A, Padron E (1948) Fasciolasis hepática con carácter de brote epidémico. Rev Cubana Med Trop 4:92–97Google Scholar
  11. Arjona R, Riancho JA, Aguado JM, Salesa R, González-Macías J (1995) Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine 74:13–23PubMedCrossRefGoogle Scholar
  12. Artigas P, Bargues MD, Mera y Sierra R, Agramunt VH, Mas-Coma S (2011) Characterisation of fascioliasis lymnaeid intermediate hosts from Chile by DNA sequencing, with emphasis on Lymnaea viator and Galba truncatula. Acta Trop 120:245–257PubMedCrossRefGoogle Scholar
  13. Ashrafi K, Massoud J, Houlakuei K, Mahmoodi M, Joafshani MA, Valero MA, Freire Fuentes MF, Khoubbane M, Artigas P, Mas-Coma S (2004) Evidence suggesting that Fasciola gigantica may be the most prevalent causal agent of fascioliasis in the endemic province of Gilan, northern Iran. Iran J Public Health 33:31–37Google Scholar
  14. Ashrafi K, Valero MA, Massoud J, Sobhani A, Solaymani-Mohammadi S, Conde P, Khoubbane M, Bargues MD, Mas-Coma S (2006a) Plant-borne human contamination by fascioliasis. Am J Trop Med Hyg 75:295–302PubMedCrossRefGoogle Scholar
  15. Ashrafi K, Valero MA, Panov AM, Periago MV, Massoud J, Mas-Coma S (2006b) Phenotypic analysis of adults of Fasciola hepatica, Fasciola gigantica and intermediate forms from the endemic region of Gilan, Iran. Parasitol Int 55:249–260PubMedCrossRefGoogle Scholar
  16. Bargues MD, Vigo M, Horak P, Dvorak J, Patzner RA, Pointier JP, Jackiewicz M, Meier-Brook C, Mas-Coma S (2001) European Lymnaeidae (Mollusca: Gastropoda), intermediate hosts of trematodiases, based on nuclear ribosomal DNA ITS-2 sequences. Infect Genet Evol 1:85–107PubMedCrossRefGoogle Scholar
  17. Bargues MD, Horak P, Patzner RA, Pointier JP, Jackiewicz M, Meier-Brook C, Mas-Coma S (2003) Insights into the relationships of Palaearctic and Nearctic lymnaeids (Mollusca: Gastropoda) by rDNA ITS-2 sequencing and phylogeny of stagnicoline intermediate host species of Fasciola hepatica. Parasite 10:243–255PubMedCrossRefGoogle Scholar
  18. Bargues MD, Artigas P, Mera y Sierra RL, Pointier JP, Mas-Coma S (2007) Characterisation of Lymnaea cubensis, L. viatrix and L. neotropica n. sp., the main vectors of Fasciola hepatica in Latin America, by analysis of their ribosomal and mitochondrial DNA. Ann Trop Med Parasitol 101:621–641PubMedCrossRefGoogle Scholar
  19. Bargues MD, Artigas P, Khoubbane M, Flores R, Glöer P, Rojas-García R, Ashrafi K, Falkner G, Mas-Coma S (2011a) Lymnaea schirazensis, an overlooked snail distorting fascioliasis data: genotype, phenotype, ecology, worldwide spread, susceptibility, applicability. PLoS One 6:e24567PubMedPubMedCentralCrossRefGoogle Scholar
  20. Bargues MD, Gonzalez C, Artigas P, Mas-Coma S (2011b) A new baseline for fascioliasis in Venezuela: lymnaeid vectors ascertained by DNA sequencing and analysis of their relationships with human and animal infection. Parasit Vectors 4:200PubMedPubMedCentralCrossRefGoogle Scholar
  21. Bargues MD, Artigas P, Khoubbane M, Mas-Coma S (2011c) DNA sequence characterisation and phylogeography of Lymnaea cousini and related species, vectors of fascioliasis in northern Andean countries, with description of L. meridensis n. sp. (Gastropoda: Lymnaeidae). Parasit Vectors 4:132PubMedPubMedCentralCrossRefGoogle Scholar
  22. Bargues MD, Malandrini JB, Artigas P, Soria CC, Velásquez JN, Carnevale S, Mateo L, Khoubbane M, Mas-Coma S (2016) Human fascioliasis endemic areas in Argentina: multigene characterisation of the lymnaeid vectors and climatic-environmental assessment of the transmission pattern. Parasit Vectors 9:306PubMedPubMedCentralCrossRefGoogle Scholar
  23. Bargues MD, Gayo V, Sanchis J, Artigas P, Khoubbane M, Birriel S, Mas-Coma S (2017) DNA multigene characterization of Fasciola hepatica and Lymnaea neotropica and its fascioliasis transmission capacity in Uruguay, with historical correlation, human report review and infection risk analysis. PLoS Negl Trop Dis 11:e0005352PubMedPubMedCentralCrossRefGoogle Scholar
  24. Barker SC, Blair D, Garret AR, Cribb TH (1993) Utility of the D1 domain of nuclear 28S rRNA for phylogenetic inference in the Digenea. Syst Parasitol 26:181–188CrossRefGoogle Scholar
  25. Bjorland J, Bryan RT, Strauss W, Hillyer GV, McAuley JB (1995) An outbreak of acute fascioliasis among Aymara Indians in the Bolivian Altiplano. Clin Infect Dis 21:1228–1233PubMedCrossRefGoogle Scholar
  26. Black J, Ntusi N, Stead P, Mayosi B, Mendelson M (2013) Human fascioliasis in South Africa. S Afr Med J 103:658–659PubMedCrossRefGoogle Scholar
  27. Blair D (1993) Molecular variation in fasciolids and Paragonimus. Acta Trop 53:277–289PubMedCrossRefGoogle Scholar
  28. Blair D, McManus DP (1989) Restriction enzyme mapping of ribosomal DNA can distinguish between fasciolid (liver fluke) species. Mol Biochem Parasitol 36:201–208PubMedCrossRefGoogle Scholar
  29. Botros SS, El-Lakkany NM, Badawy AA, Mahmoud SS, Ebeid FA, Fenwick A (2009) Mirazid shows insignificant activity against ovine fascioliasis. Ann Trop Med Parasitol 103:605–616PubMedCrossRefGoogle Scholar
  30. Brady MT, O’Nneill SM, Dalton JP, Mills KH (1999) Fasciola hepatica suppresses a protective Th1 response against Bordetella pertussis. Infect Immun 67:5372–5378PubMedPubMedCentralGoogle Scholar
  31. Brennan GP, Fairweather I, Trudgett A, Hoey E, McCoy, McConville M, Meaney M, Robinson M, McFerran N, Ryan L, Lanusse C, Mottier L, Alvarez L, Solana H, Virkel G, Brophy PM (2007) Understanding triclabendazole resistance. Exp Mol Pathol 82:104–109PubMedCrossRefPubMedCentralGoogle Scholar
  32. Brito Alberto E, Hernandez Barreto MA, De La Fe RP, Silveira Pardo EA (2010) Prevalencia, decomisos de hígado y pérdidas económicas por Fasciola hepatica en mataderos bovinos de tres provincias de la región central de Cuba. REDVET Revista Electrónica de Veterinaria 11:1–7Google Scholar
  33. Carnevale S, Rodriguez MI, Guarnera EA, Carmona C, Tanos T, Angel SO (2001) Immunodiagnosis of fasciolosis using recombinant procathepsin L cysteine proteinase. Diagn Microbiol Infect Dis 41:43–49PubMedCrossRefPubMedCentralGoogle Scholar
  34. Carnevale S, Cabrera MG, Cucher MA, di Risio CA, Malandrini JB, Kamenetzky L, Alazraqui M, Etchart CB, Pantano ML, Velásquez JN (2013) Direct, immunological and molecular techniques for a fasciolosis survey in a rural area of San Luis, Argentina. J Parasit Dis 37:251–259PubMedCrossRefPubMedCentralGoogle Scholar
  35. Chen MG, Mott KE (1990) Progress in assessment of morbidity due to Fasciola hepatica infection: a review of recent literature. Trop Dis Bull 87:R1–R38Google Scholar
  36. Chen JX, Chen MX, Ai L, Xu XN, Jiao JM, Zhu TJ, Su HY, Zang W, Luo JJ, Guo YH, Lv S, Zhou XN (2013) An outbreak of human fascioliasis gigantica in Southwest China. PLoS One 8:e71520PubMedPubMedCentralCrossRefGoogle Scholar
  37. Clay RC, Straight WM (1961) Surgical removal of liver flukes from the common bile duct. JAMA 177:786–788PubMedCrossRefPubMedCentralGoogle Scholar
  38. Cordova M, Herrera P, Nopo L, Bellatin J, Naquira C, Guerra H, Espinoza JR (1997) Fasciola hepatica cysteine proteinases: immunodominant antigens in human fascioliasis. Am J Trop Med Hyg 57:660–666PubMedCrossRefPubMedCentralGoogle Scholar
  39. Cordova M, Reategui L, Espinoza JR (1999) Immunodiagnosis of human fascioliasis with Fasciola hepatica cysteine proteinases. Trans R Soc Trop Med Hyg 93:54–57PubMedCrossRefPubMedCentralGoogle Scholar
  40. Coudert J, Triozon F (1958) Recherche sur l’épidémiologie de la distomatose humaine à Fasciola hepatica. A propos d’une épidémie récente de 500 cas. Rev Hyg Med Soc 6:840–864PubMedGoogle Scholar
  41. Curtale F, Hammoud ES, El Wakeel A, Mas-Coma S, Savioli L (2000) Human fascioliasis, an emerging public health problem in the Nile Delta, Egypt. Res Rev Parasitol 60:129–134Google Scholar
  42. Curtale F, Hassanein YAE, El Wakeel A, Mas-Coma S, Montresore A (2003a) Distribution of human fascioliasis by age and gender among rural population in the Nile Delta, Egypt. J Trop Pediatr 49:264–268PubMedCrossRefGoogle Scholar
  43. Curtale F, Mas-Coma S, Hassanein YAE, Barduagni P, Pezzotti P, Savioli L (2003b) Clinical signs and household characteristics associated with human fascioliasis among rural population in Egypt: a case-control study. Parassitologia 45:5–11PubMedGoogle Scholar
  44. Cwiklinski K, Dalton JP, Dufresne PJ, La Course J, Williams DJ, Hodgkinson J, Paterson S (2015) The Fasciola hepatica genome: gene duplication and polymorphism reveals adaptation to the host environment and the capacity for rapid evolution. Genome Biol 16:71PubMedPubMedCentralCrossRefGoogle Scholar
  45. Dalton JP, Robinson MW, Mulcahy G, O'Neill SM, Donnelly S (2013) Immunomodulatory molecules of Fasciola hepatica: candidates for both vaccine and immunotherapeutic development. Vet Parasitol 195:272–285PubMedCrossRefGoogle Scholar
  46. Danis M, Nozais JP, Chandenier J (1985) La distomatose à Fasciola hepatica. II: La fasciolose humaine en France. L'Action Vétérinaire 907:VII–VIIIGoogle Scholar
  47. De La Torre EE, Manzano-Román R, Valero L, Oleaga A, Pérez-Sánchez R, Hernández-González A, Siles-Lucas M (2011) Comparative proteomic analysis of Fasciola hepatica juveniles and Schistosoma bovis schistosomula. J Proteomics 74:1534–1544CrossRefGoogle Scholar
  48. De NV, Murrell KD, Cong LD, Cam PD, Chaule V, Toan ND, Dalsgaard A (2003) The food-borne trematode zoonoses of Vietnam. Southeast Asian J Trop Med Public Health 34:S12–S34Google Scholar
  49. De NV, Le TH, Waikagul, J (2006) Planborne trematodes and fascioliasis in Vietnam. In: Paper presented at the 5th Seminar on food- and water-borne parasitic zoonoses, Bangkok, 28–30 November 2006Google Scholar
  50. Del Risco Barrios U, Vazquez Drake CT, Garcia Gonzalez G, Sánchez Casas A (2001) Evaluación de la excreción de huevos de Fasciola hepatica por tres esquemas terapéuticos. Archivo Médico de Camagüey 5:4Google Scholar
  51. Diaz Fernandez R, Garces Martinez M, Millan Alvarez LM, Perez Lastre J, Millan Marcelo JC (2011) Comportamiento clínico-terapéutico de Fasciola hepatica en una serie de 87 pacientes. Rev Cubana Med Trop 63:268–274PubMedPubMedCentralGoogle Scholar
  52. El-Morshedy H, Farghaly A, Sharaf S, Abou-Basha L, Barakat R (1999) Triclabendazole in the treatment of human fascioliasis: a community-based study. East Mediterr Health J 5:888–894PubMedPubMedCentralGoogle Scholar
  53. Espinoza JR, Maco V, Marcos L, Saez S, Neyra V, Terashima A, Samalvides F, Gotuzzo E, Chavarry E, Huaman MC, Bargues MD, Valero MA, Mas-Coma S (2007) Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. Am J Trop Med Hyg 76:977–982PubMedCrossRefGoogle Scholar
  54. Esteban JG, Flores A, Aguirre C, Strauss W, Angles R, Mas-Coma S (1997a) Presence of very high prevalence and intensity of infection with Fasciola hepatica among Aymara children from the northern Bolivian Altiplano. Acta Trop 66:1–14PubMedCrossRefGoogle Scholar
  55. Esteban JG, Flores A, Angles R, Strauss W, Aguirre C, Mas-Coma S (1997b) A population-based coprological study of human fascioliasis in a hyperendemic area of the Bolivian Altiplano. Trop Med Int Health 2:695–699PubMedCrossRefGoogle Scholar
  56. Esteban JG, Bargues MD, Mas-Coma S (1998) Geographical distribution, diagnosis and treatment of human fascioliasis: a review. Res Rev Parasitol 58:13–42Google Scholar
  57. Esteban JG, Flores A, Angles R et al (1999) High endemicity of human fascioliasis between Lake Titicaca and La Paz valley, Bolivia. Trans R Soc Trop Med Hyg 93:151–156PubMedCrossRefGoogle Scholar
  58. Esteban JG, Gonzalez C, Bargues MD, Mas-Coma S (2002) High fascioliasis infection in children linked to a man-made irrigation zone in Peru. Trop Med Int Health 7:339–348PubMedCrossRefGoogle Scholar
  59. Esteban JG, Gonzalez C, Curtale F, Muñoz-Antoli C, Valero MA, Bargues MD, El-Sayed M, El-Wakeel AA, Abdel-Wahab Y, Montresor A, Engels D, Savioli L, Mas-Coma S (2003) Hyperendemic fascioliasis associated with schistosomiasis in villages of the Nile Delta, Egypt. Am J Trop Med Hyg 69:429–437PubMedCrossRefGoogle Scholar
  60. Fairweather I (2005) Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol 79:227–234PubMedCrossRefGoogle Scholar
  61. Fairweather I (2009) Triclabendazole progress report, 2005–2009: an advancement of learning? J Helminthol 83:139–150PubMedCrossRefGoogle Scholar
  62. Fairweather I, Boray JC (1999) Fasciolicides: efficacy, action, resistance and its management. Vet J 158:81–112PubMedCrossRefGoogle Scholar
  63. Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF (2003) Double blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 17:265–270PubMedCrossRefGoogle Scholar
  64. Fentie T, Ergoiu S, Gedefaw M, Desta A (2013) Epidemiology of human fascioliasis and intestinal parasitosis among schoolchildren in Lake Tana Basin, Northwest Ethiopia. Trans R Soc Trop Med Hyg 107:480–486PubMedCrossRefGoogle Scholar
  65. Gaasenbeek CPH, Moll L, Cornelissen JBWJ, Vellema P, Borgsteede FH (2001) An experimental study on triclabendazole resistance of Fasciola hepatica in sheep. Vet Parasitol 95:37–43PubMedCrossRefGoogle Scholar
  66. Gaillet P, Liance M, Rivollet D, Houin R (1983) Situation de la fasciolose humaine en France, enquête retrospective portant sur les 30 dernières années. Bulletin de la Société Française de Parasitologie 1:79–82Google Scholar
  67. Gargala G, Abboud P, Borsa-Lebas F (2005) Case report of successful treatment of triclabendazole resistant fascioliasis by nitazoxanide. In: Paper presented at the Medicine and Health in the Tropics (XVIth International Congress for Tropical Medicine and Malaria). Marseille, 11–15 Sept, 2005Google Scholar
  68. Giap LH (1987) Distomatose hépatique à Fasciola hepatica. Université de Bordeaux II, Bordeaux, Laboratoire de ParasitologieGoogle Scholar
  69. Girones N, Valero MA, Garcia-Bodelon MA, Chico-Calero I, Punzón C, Fresno M, Mas-Coma S (2007) Immune suppression in advanced chronic fascioliasis: an experimental study in a rat model. J Infect Dis 195:1504–1512PubMedCrossRefGoogle Scholar
  70. Gonzales-Santana B, Dalton JP, Vasquez-Camargo F, Parkinson M, Ndao M (2013) The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease. PLoS Negl Trop Dis 7:e2414PubMedPubMedCentralCrossRefGoogle Scholar
  71. Gonzalez LC, Esteban JG, Bargues MD, Valero MA, Ortiz P, Náquira C, Mas-Coma S (2011) Hyperendemic human fascioliasis in Andean valleys: an altitudinal transect analysis in children of Cajamarca province, Peru. Acta Trop 120:119–129PubMedCrossRefGoogle Scholar
  72. Gonzalez-Miguel J, Valero MA, Reguera-Gome ZM, Mas-Bargues C, Bargues MD, Simón F, Mas-Coma S (2019) Numerous Fasciola plasminogen-binding proteins may underlie blood-brain barrier leakage and explain neurological disorder complexity and heterogeneity in the acute and chronic phases of human fascioliasis. Parasitology 146: 284–298PubMedPubMedCentralCrossRefGoogle Scholar
  73. Haseeb AN, El Shazly AM, Arafa MAS, Morsy AT (2002) A review on fascioliasis in Egypt. J Egypt Soc Parasitol 32:317–335PubMedGoogle Scholar
  74. Hien TT, Truong NT, Minh NH, Dat HD, Dung NT, Hue NT, Dung TK, Tuan PQ, Campbell JI, Farrar JJ, Day JN (2008) A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in Central Vietnam. Am J Trop Med Hyg 78:388–392PubMedCrossRefGoogle Scholar
  75. Hillyer GV (1981) Fascioliasis in Puerto Rico: a review. Bol Asoc Med P R 73:94–101PubMedGoogle Scholar
  76. Hillyer GV (1999) Immunodiagnosis of human and animal fasciolosis. In: Dalton JP (ed) Fasciolosis. CAB International, Oxon, pp 435–447Google Scholar
  77. Hillyer GV, Soler de Galanes M, Rodriguez-Perez J, Bjorland J, Silva de Lagrava M, Ramirez-Guzman S, Bryan RT (1992) Use of the falcon assay screening test-enzyme-linked immunosorbent assay (FAST-ELISA) and the enzyme-linked immunoelectrotransfer blot (EITB) to determine the prevalence of human fascioliasis in the Bolivian Altiplano. Am J Trop Med Hyg 46:603–609PubMedCrossRefGoogle Scholar
  78. Huang WY, He B, Wang CR, Zhu XQ (2004) Characterisation of Fasciola species from Mainland China by ITS-2 ribosomal DNA sequence. Vet Parasitol 120:75–83PubMedCrossRefGoogle Scholar
  79. Hung NM, Dung DT (2011) Controlling helminthiasis period 2006-2010 and study in next period 2011-2015 in Vietnam. Bull Natl Inst Malariol Parasitol Entomol 2:7–15Google Scholar
  80. Hurtrez-Bousses S, Durand P, Jabbour-Zahab R, Guégan JF, Meunier C, Bargues MD, Mas-Coma S, Renaud F (2004) Isolation and characterization of microsatellite markers in the liver fluke (Fasciola hepatica). Mol Ecol Notes 4:689–690CrossRefGoogle Scholar
  81. Ikeda T (1998) Cystatin capture enzyme-linked immunosorbent assay for immunodiagnosis of human paragonimiasis and fascioliasis. Am J Trop Med Hyg 59:286–290PubMedCrossRefGoogle Scholar
  82. Inoue K, Kanemasa H, Inoue K, Matsumoto M, Kajita Y, Mitsufuji S, Kataoka K, Okanoue T, Yamada M, Uchikawa R, Tegoshi T, Arizono N (2007) A case of human fasciolosis: discrepancy between egg size and genotype of Fasciola sp. Parasitol Res 100:665–667PubMedCrossRefGoogle Scholar
  83. Intapan PM, Mallewong W, Wongkham C, Tomanakarn K, Ieamviteevanich K, Pipitgool V, Sukolapong V (1998) Excretory-secretory antigen components of adult Fasciola gigantica recognized by infected human sera. Southeast Asian J Trop Med Public Health 29:579–583PubMedGoogle Scholar
  84. Intapan PM, Sadee P, Wongkham C, Maleewong W (2004) Development of rapid agglutination test using Fasciola gigantica specific antigen for serodiagnosis of human fascioliasis. Southeast Asian J Trop Med Public Health 35:S313–S317Google Scholar
  85. Jaffar Z, Sivakuru T, Roberts K (2004) CD4(+) CD25(+) T cells regulate airway eosinophilic inflammation by modulating the Th2 cell phenotype. J Immunol 172:3842–3849PubMedCrossRefGoogle Scholar
  86. Kabil SM, El Ashry E, Ashraf NK (2000) An open-label clinical study of nitazoxanide in the treatment of human fascioliasis. Curr Therapeut Res 61:339–345CrossRefGoogle Scholar
  87. Keiser J, Sayed H, El-Ghanam M, Sabry H, Anani S, El-Wakeel A, Hatz C, Utzinger J, El-Din SS, El-Maadawy W, Botros S (2011) Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS Negl Trop Dis 5:e1285PubMedPubMedCentralCrossRefGoogle Scholar
  88. Kouri P, Arenas R (1932) La distomatosis hepática en Cuba. Tomo I, La Propagandista, La Habana, CubaGoogle Scholar
  89. Le TH, Blair D, McManus DP (2001) Complete DNA sequence and gene organization of the mitochondrial genome of the liver fluke, Fasciola hepatica L. (Plathelminthes; Trematoda). Parasitology 123:609–621PubMedCrossRefGoogle Scholar
  90. Le TH, Nguyen KT, Nguyen NTB, Doan HT, Le XT, Hoang CT, De NV (2012) Development and evaluation of a single step duplex PCR for simultaneous detection of Fasciola hepatica and Fasciola gigantica (Fasciolidae; Trematoda; Platyhelminthes). J Clin Microbiol 50:2720–2726PubMedPubMedCentralCrossRefGoogle Scholar
  91. Lecaillon JB, Gobdillon J, Campestrini J (1998) Effect of food on bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 45:601–604PubMedPubMedCentralCrossRefGoogle Scholar
  92. Lee CG, Zimmerman GL, Bishop JK (1992) Host influence on the banding profiles of wholebody protein and excretory-secretory product of Fasciola hepatica (Trematoda) by isoelectric focusing. Vet Parasitol 41:57–68PubMedCrossRefGoogle Scholar
  93. Losos GJ (1986) Infectious tropical diseases of domestic animals. Longman Scientific & Technical, EssexGoogle Scholar
  94. Lukambagire AS, Mchaile DN, Nyindo M (2015) Diagnosis of human fascioliasis in Arusha region, northern Tanzania by microscopy and clinical manifestations in patients. BMC Infect Dis 15:578PubMedPubMedCentralCrossRefGoogle Scholar
  95. Maleewong W, Wongkham C, Intapan PM, Pipitgool V (1999) Fasciola gigantica-specific antigens: purification by a continuous-elution method and its evaluation for the diagnosis of human fascioliasis. Am J Trop Med Hyg 61:648–651PubMedCrossRefGoogle Scholar
  96. Marcilla A, Bargues MD, Mas-Coma S (2002) A PCR-RFLP assay for the distinction between Fasciola hepatica and F. gigantica. Mol Cell Probes 16:327–333PubMedCrossRefGoogle Scholar
  97. Marcos LA, Busalleu A, Terashima A, Espinoza JR (2009) Detection of antibodies against Fasciola hepatica in cirrhotic patients from Peru. J Helminthol 83:23–26PubMedCrossRefGoogle Scholar
  98. Marcos-Raymundo LA, Maco-Flores V, Terashima-Iwashita A, Frine-Samalvides C, Gotuzzo E (2002) Características clínicas de la infección crómica por Fasciola hepatica en niños. Rev Gastroenterol Peru 22:228–233PubMedGoogle Scholar
  99. Martinez-Sernandez V, Muiño L, Perteguer MJ, Gárate T, Mezo M, González-Warleta M, Muro A, Correia da Costa JM, Romarís F, Ubeira FM (2011) Development and evaluation of a new lateral flow immunoassay for serodiagnosis of human fasciolosis. PLoS Negl Trop Dis 5:e1376PubMedPubMedCentralCrossRefGoogle Scholar
  100. Mas-Coma S (2004a) Human fascioliasis. In: Cotruvo JA, Dufour A, Rees G, Bartram J, Carr R, Cliver DO, Craun GF, Fayer R, Gannon VPJ (eds) Waterborne zoonoses: identification, causes and control. World Health Organization (WHO), London, pp 305–322Google Scholar
  101. Mas-Coma S (2004b) Human fascioliasis: epidemiological patterns in human endemic areas of South America, Africa and Asia. Southeast Asian J Trop Med Public Health 35:1–11Google Scholar
  102. Mas-Coma S (2005) Epidemiology of fascioliasis in human endemic areas. J Helminthol 79:207–216PubMedCrossRefGoogle Scholar
  103. Mas-Coma S, Bargues MD (1997) Human liver flukes: a review. Res Rev Parasitol 57:145–218Google Scholar
  104. Mas-Coma S, Bargues MD (2009) Populations, hybrids and the systematic concepts of species and subspecies in Chagas disease triatomine vectors inferred from nuclear ribosomal and mitochondrial DNA. Acta Trop 110:112–136PubMedCrossRefGoogle Scholar
  105. Mas-Coma S, Fons R, Feliu C, Bargues MD, Valero MA, Galan-Puchades MT (1987) Conséquences des phènomènes liés à l’insularité dans les maladies parasitaires. La grande douve du foie (Fasciola hepatica) et les Muridés en Corse. Bulletin de la Société Neuchâteloise des Sciences Naturelles 110:57–62Google Scholar
  106. Mas-Coma S, Fons R, Feliu C, Bargues MD, Valero MA, Galan-Puchades MT (1988) Small mammals as natural definitive hosts of the liver fluke, Fasciola hepatica Linnaeus, 1758 (Trematoda: Fasciolidae): a review and two new records of epidemiologic interest on the island of Corsica. Riv Parassitol 5:73–78Google Scholar
  107. Mas-Coma S, Esteban JG, Bargues MD (1999a) Epidemiology of human fascioliasis: a review and proposed new classification. Bull World Health Organ 77:340–346PubMedPubMedCentralGoogle Scholar
  108. Mas-Coma S, Bargues MD, Esteban JG (1999b) Human fasciolosis. In: Dalton JP (ed) Fasciolosis. CAB International, Oxon, pp 411–434Google Scholar
  109. Mas-Coma S, Angles R, Esteban JG, Bargues MD, Buchon P, Franken M, Strauss W (1999c) The northern Bolivian Altiplano: a region highly endemic for human fascioliasis. Trop Med Int Health 4:454–467PubMedCrossRefGoogle Scholar
  110. Mas-Coma S, Bargues MD, Marty AM, Marty AM, Neafie RC (2000) Hepatic trematodiases. In: Meyers WM, Neafie AM, Marty AM, Wear DJ (eds) Pathology of infectious diseases, Helminthiases, vol 1. Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC, pp 69–92Google Scholar
  111. Mas-Coma S, Funatsu IR, Bargues MD (2001) Fasciola hepatica and lymnaeid snails occurring at very high altitude in South America. Parasitology 123:S115–S127PubMedCrossRefGoogle Scholar
  112. Mas-Coma S, Bargues MD, Valero MA, Fuentes MV (2003) Adaptation capacities of Fasciola hepatica and their relationships with human fascioliasis: from below sea level up to the very high altitude. In: Combes C, Jourdane J (eds) Taxonomy, ecology and evolution of metazoan parasites, vol 2. Presses Universitaires de Perpignan, Perpignan, pp 81–123Google Scholar
  113. Mas-Coma S, Bargues MD, Valero MA (2005) Fascioliasis and other plant-borne trematode zoonoses. Int J Parasitol 35:1255–1278PubMedCrossRefPubMedCentralGoogle Scholar
  114. Mas-Coma S, Bargues MD, Valero MA (2007) Plantborne trematode zoonoses: fascioliasis and fasciolopsiasis. In: Murrell D, Fried B (eds) World class parasites, Food-borne parasites, fish and plant-borne parasites, vol 11. Springer, New YorkGoogle Scholar
  115. Mas-Coma S, Valero MA, Bargues MD (2009a) Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol 69:41–146PubMedCrossRefPubMedCentralGoogle Scholar
  116. Mas-Coma S, Valero MA, Bargues MD (2009b) Climate change effects on trematodiases, with emphasis on zoonotic fascioliasis and schistosomiasis. Vet Parasitol 163:264–280PubMedCrossRefGoogle Scholar
  117. Mas-Coma S, Agramunt VH, Valero MA (2013) Direct and indirect affection of the central nervous system by Fasciola infection. Handb Clin Neurol 114:297–310PubMedCrossRefGoogle Scholar
  118. Mas-Coma S, Agramunt VH, Valero MA (2014a) Neurological and ocular fascioliasis in humans. Adv Parasitol 84:27–149PubMedCrossRefGoogle Scholar
  119. Mas-Coma S, Bargues MD, Valero MA (2014b) Diagnosis of human fascioliasis by stool and blood techniques: update for the present global scenario. Parasitology 141:S1918–S1946CrossRefGoogle Scholar
  120. Mas-Coma S, Bargues MD, Valero MA (2018) Human fascioliasis infection sources, their diversity, incidence factors, analytical methods and prevention measures. Parasitology 145:S1665–S1699CrossRefGoogle Scholar
  121. Massoud J (1990) Fascioliasis outbreak of man and drug test (Triclabendazol) in Caspian littoral, northern part of Iran, 1989. Bulletin de la Société Française de Parasitologie 8:S438Google Scholar
  122. Massoud, J (1993) Present status of human fascioliasis in Iran. In: Food-borne trematodes, World Health Organization, WHO Manual, Manila, Mimeogr. Rep. Sch/SG/93 w:19Google Scholar
  123. McNulty SN, Tort JF, Rinaldi G, Fischer K, Rosa BA, Smircich P, Fontenla S, Choi YJ, Tyagi R, Hallsworth-Pepin K, Mann VH, Kammili L, Latham PS, Dell'Oca N, Dominguez F, Carmona C, Fischer PU, Brindley PJ, Mitreva M (2017) Genomes of Fasciola hepatica from the Americas reveal colonization with Neorickettsia Endobacteria related to the agents of Potomac horse and human Sennetsu fevers. PLoS Genet 13:e1006537PubMedPubMedCentralCrossRefGoogle Scholar
  124. McVeigh P, Maule AG, Dalton JP, Robinson MW (2012) Fasciola hepatica virulence-associated cysteine peptidases: a systems biology perspective. Microbes Infect 14:301–310PubMedCrossRefGoogle Scholar
  125. Mera y Sierra R, Agramunt VH, Cuervo P, Mas-Coma S (2011) Human fascioliasis in Argentina: retrospective overview, critical analysis and baseline for future research. Parasit Vectors 4:104PubMedPubMedCentralCrossRefGoogle Scholar
  126. Mezo M, Gonzalez-Warleta M, Ubeira FM (2003) Optimized serodiagnosis of sheep fascioliasis by fast-D protein liquid chromatography fractionation of F. hepatica excretory-secretory antigens. J Parasitol 89:843–849PubMedCrossRefGoogle Scholar
  127. Mezo M, Gonzalez-Warleta M, Carro C, Ubeira FM (2004) An ultrasensitive capture ELISA for detection of Fasciola hepatica coproantigens in sheep and cattle using a new monoclonal antibody (MM3). J Parasitol 90:845–852PubMedCrossRefGoogle Scholar
  128. Millan JC, Mull R, Freise S, Richter J (2000) The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 63:264–269PubMedCrossRefGoogle Scholar
  129. Moghaddam AS, Massoud J, Mahmoodi M, Mahvi AH, Periago MV, Artigas P, Fuentes MV, Bargues MD, Mas-Coma S (2004) Human and animal fascioliasis in Mazandaran province, northern Iran. Parasitol Res 94:61–69PubMedCrossRefGoogle Scholar
  130. O’Neill SM, Parkinson SM, Strauss W et al (1998) Immunodiagnosis of Fasciola hepatica (Fascioliasis) in a human population in the Bolivian Altiplano using purifi ed cathepsin L cysteine proteinase. Am J Trop Med Hyg 58:417–423PubMedCrossRefGoogle Scholar
  131. O’Neill SM, Parkinson SM, Dowd AJ, Strauss W, Angles R, Dalton JP (1999) Immunodiagnosis of human fascioliasis using recombinant Fasciola hepatica cathepsin L1 cysteine proteinase. Am J Trop Med Hyg 60:749–751PubMedCrossRefPubMedCentralGoogle Scholar
  132. O’Neill SM, Brady MT, Callanan JJ, Mulcahy G, Joyce P, Mills KH, Dalton JP (2000) Fasciola hepatica infection downregulates Th1 responses in mice. Parasite Immunol 22:147–155PubMedCrossRefGoogle Scholar
  133. Olaechea F, Lovera V, Larroza M, Raffo F, Cabrera R (2011) Resistance of Fasciola hepatica against triclabendazole in cattle in Patagonia (Argentina). Vet Parasitol 178:364–366PubMedCrossRefPubMedCentralGoogle Scholar
  134. Oliveira DR, Ferreira DM, Stival CC, Romero F, Cavagnolli F, Kloss A, Araújo FB, Molento MB (2008) Triclabendazole resistance involving Fasciola hepatica in sheep and goats during an outbreak in Almirante Tamandare, Parana, Brazil. Rev Bras Parasitol Vet 17:S149–S153CrossRefGoogle Scholar
  135. Ortiz P, Scarcella S, Cerna C, Rosales C, Cabrera M, Guzmán M, Lamenza P, Solana H (2013) Resistance of Fasciola hepatica against triclabendazole in cattle in Cajamarca (Peru): a clinical trial and in vive efficacy test in sheep. Vet Parasitol 195:118–121PubMedCrossRefPubMedCentralGoogle Scholar
  136. Periago MV, Valero MA, Panova M, Mas-Coma S (2006) Phenotypic comparison of allopatric populations of Fasciola hepatica and Fasciola gigantica from European and African bovines using a computer image analysis system (CIAS). Parasitol Res 99:368–378PubMedCrossRefPubMedCentralGoogle Scholar
  137. Periago MV, Valero MA, El Sayed M, Ashrafi K, El Wakeel A, Mohamed MY, Desquesnes M, Curtale F, Mas-Coma S (2008) First phenotypic description of Fasciola hepatica / Fasciola gigantica intermediate forms from the human endemic area of the Nile Delta, Egypt. Infect Genet Evol 8:51–58PubMedCrossRefGoogle Scholar
  138. Quang TD, Duong TH, Richard-Lenoble D, Odermatt P, Khammanivong K (2008) Emergence chez l’homme de fasciolose à Fasciola gigantica et de distomatose intestinale à Fasciolopsis buski au Laos. Cahiers Santé 18:119–124PubMedGoogle Scholar
  139. Qureshi AW, Tanveer A, Mas-Coma S (2016) Epidemiological analysis of human fascioliasis in northeastern Punjab, Pakistan. Acta Trop 156:157–164PubMedCrossRefGoogle Scholar
  140. Qureshi AW, Zeb A, Mansoor A, Hayat A, Mas-Coma S (2019) Fasciola hepatica infection in children actively detected in a survey in rural areas of Mardan district, Khyber Pakhtunkhawa province, northern Pakistan. Parasitol Int 69:39–46PubMedCrossRefGoogle Scholar
  141. Raymundo LA, Maco Flores V, Terashima A, Samalvides F, Miranda E, Tantalean M, Espinoza JR, Gotuzzo E (2004) Hiperendemicidad de Fasciolosis humana en el Valle del Mantaro, Perú: factores de riesgo de la infeccion por Fasciola hepatica. Rev Gastroenterol Peru 24:158–164PubMedGoogle Scholar
  142. Ripert C, Tribouley J, Luang Dinh Giap G, Combe A, Laborde M (1987) Epidémiologie de la fasciolose humaine dans le sud ouest de la France. Bulletin de la Société Française de Parasitologie 5:227–230Google Scholar
  143. Roberts JA, Suhardono (1996) Approaches to the control of fasciolosis in ruminants. Int J Parasitol 26:971–981PubMedCrossRefGoogle Scholar
  144. Rojas L, Vazquez A, Domenech I, Robertson LJ (2009) Fascioliasis: can Cuba conquer this emerging parasitosis? Trends Parasitol 26:26–34PubMedCrossRefGoogle Scholar
  145. Rokni MB, Massoud J, O’Neill SM, Parkinson M, Dalton JP (2002) Diagnosis of human fasciolosis in the Gilan province of northern Iran: application of cathepsin L-ELISA. Diagn Microbiol Infect Dis 44:175–179PubMedCrossRefGoogle Scholar
  146. Rokni MB, Mirhendi H, Mizani A, Mohebali M, Sharbatkhori M, Kia EB, Abdoli H, Izadi S (2010) Identification and differentiation of Fasciola hepatica and Fasciola gigantica using a simple PCR-restriction enzyme method. Exp Parasitol 124:209–213PubMedCrossRefPubMedCentralGoogle Scholar
  147. Rondelaud D, Belfaiza M, Vignoles P, Moncef M, Dreyfuss G (2009) Redial generations of Fasciola hepatica: a review. J Helminthol 83:245–254PubMedCrossRefGoogle Scholar
  148. Rossignol JF, Abaza H, Friedman H (1998) Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg 92:103–104PubMedCrossRefGoogle Scholar
  149. Sah R, Khadka S, Lakhey PJ, Pradhan S, Shah NP, Singh YP, Mas-Coma S (2018) Human case of Fasciola gigantica-like infection, review of human fascioliasis reports in Nepal, and epidemiological analysis within the south Central Asia. Acta Parasitol 63:435–443PubMedCrossRefGoogle Scholar
  150. Sampaio-Silva ML, Correia da Costa JM, Viana da Costa AM, Pires MA, Lopes SA, Castro AM, Monjour L (1996) Antigenic components of excretory-secretory products of adult Fasciola hepatica recognized in human infections. Am J Trop Med Hyg 54:146–148PubMedCrossRefGoogle Scholar
  151. Savioli L, Chistulo L, Montresor A (1999) New opportunities for the control of fascioliasis. Bull World Health Organ 77:300PubMedPubMedCentralGoogle Scholar
  152. Semyenova SK, Morozova EV, Chrisanfova GG (2003) RAPD variability and genetic diversity in two populations of liver fluke, Fasciola hepatica. Acta Parasitol 48:125–130Google Scholar
  153. Sorribes J, Aubary MJ, Bargues MD et al (1990) Revisión de los casos humanos de Fascioliasis en España entre los años 1970 y 1989. In: Paper presented at the Congreso de Zoonosis, 1° Interautonómico, Reunión de la International Zoonoses Association (IZA), Valencia, SpainGoogle Scholar
  154. Spithill TW, Smooker PM, Copeman DB (1999) Fasciola gigantica: epidemiology, control, immunology and molecular biology. In: Dalton JP (ed) Fasciolosis. CAB International, Oxon, pp 465–525Google Scholar
  155. Spithill TW, Carmona C, Piedrafita D, Smooker PM (2012) Prospects for immunoprophylaxis against Fasciola hepatica (liver fluke). In: Caffrey CR, Selzer M (eds) Parasitic helminths: targets, screens, drugs and vaccines. Wiley, Weinheim, pp 465–484CrossRefGoogle Scholar
  156. Strauss W, O’Neill SM, Parkinson M, Angles R, Dalton JP (1999) Diagnosis of human fascioliasis: detection of anti-cathepsin L antibodies in blood samples collected on filter paper. Am J Trop Med Hyg 60:746–748PubMedCrossRefPubMedCentralGoogle Scholar
  157. Talaie H, Emami H, Yadegarinia D, Nava-Ocampo AA, Massoud J, Azmoudeh M, Mas-Coma S (2004) Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis. Clin Exp Pharmacol Physiol 31:777–782PubMedCrossRefPubMedCentralGoogle Scholar
  158. Tantrawatpan C, Maleewong W, Wongkham C, Wongkham S, Intapan PM, Nakashima K (2005) Serodiagnosis of human fascioliasis by cystatin capture enzyme-linked immunosorbent assay with recombinant Fasciola gigantica capthespsin L antigen. Am J Trop Med Hyg 72:82–86PubMedCrossRefPubMedCentralGoogle Scholar
  159. Tinar R (1984) Yumurta boyutlarina gore Fasciola gigantica ile Fasciola hepatica’ nin ayirimi uzerinde arastirmalar. Ankara Üniversitesi Veteriner Fakültesi 31:207–229Google Scholar
  160. Torgerson P, Claxton J (1999) Epidemiology and control. In: Dalton JP (ed) Fasciolosis. CAB International, Oxon, pp 113–149Google Scholar
  161. Trueba G, Guerrero T, Fornasini M, Casariego I, Zapata S, Ontaneda S, Vasco L (2000) Detection of Fasciola hepatica infection in a community located in the Ecuadorian Andes. Am J Trop Med Hyg 62:518PubMedCrossRefPubMedCentralGoogle Scholar
  162. Tum S, Puotinen ML, Copeman DB (2004) A geographic information system model for mapping risk of fasciolosis in cattle and buffaloes in Cambodia. Vet Parasitol 122:141–149PubMedCrossRefPubMedCentralGoogle Scholar
  163. Tum S, Puotinen ML, Skerratt LF, Chan B, Sothoeun S (2007) Validation of a geographic information system model for mapping the risk of fasciolosis in cattle and buffaloes in Cambodia. Vet Parasitol 143:364–367PubMedCrossRefPubMedCentralGoogle Scholar
  164. Turrientes MC, Saenz de Santamaria A, Ceballos E, Díaz M, Barreno M, Muro A, Pardo J, López-Vélez R (2004) Fasciolosis importada y autóctona. Enfermedades Emergentes 6:188Google Scholar
  165. Ubeira FM, Muiño L, Valero MA, Periago MV, Pérez-Crespo I, Mezo M, González-Warleta M, Romarís F, Paniagua E, Cortizo S, Llovo J, Más-Coma S (2009) MM3-ELISA detection of Fasciola hepatica coproantigens in preserved human stool samples. Am J Trop Med Hyg 81:156–162PubMedCrossRefGoogle Scholar
  166. Valero MA, Mas-Coma S (2000) Comparative infectivity of Fasciola hepatica metacercariae from isolates of the main and secondary reservoir animal host species in the Bolivian Altiplano high human endemic region. Folia Parasitol 47:17–22PubMedCrossRefGoogle Scholar
  167. Valero MA, Darce NA, Panova M, Mas-Coma S (2001) Relationships between host species and morphometric patterns in Fasciola hepatica adults and eggs from the northern Bolivian Altiplano hyperendemic region. Vet Parasitol 102:85–100PubMedCrossRefGoogle Scholar
  168. Valero MA, Santana M, Morales M, Hernandez JL, Mas-Coma S (2003) Risk of gallstone disease in advanced chronic phase of fascioliasis: an experimental study in a rat model. J Infect Dis 188:787–793PubMedCrossRefGoogle Scholar
  169. Valero MA, De Renzi M, Panova M, Garcia-Bodelon MA, Periago MV, Ordoñez D, Mas-Coma S (2006a) Crowding effect on adult growth, pre-patent period and egg shedding of Fasciola hepatica. Parasitology 133:453–463PubMedCrossRefGoogle Scholar
  170. Valero MA, Navarro M, Garcia-Bodelon MA, Marcilla A, Morales M, Hernandez JL, Mengual P, Mas-Coma S (2006b) High risk of bacterobilia in advanced experimental chronic fasciolosis. Acta Trop 100:17–23PubMedCrossRefGoogle Scholar
  171. Valero MA, Girones N, Garcia-Bodelon MA, Periago MV, Chico-Calero I, Khoubbane M, Fresno M, Mas-Coma S (2008) Anaemia in advanced chronic fasciolosis. Acta Trop 108:35–43PubMedCrossRefGoogle Scholar
  172. Valero MA, Perez-Crespo I, Periago MV, Khoubbane M, Mas-Coma S (2009) Fluke egg characteristics for the diagnosis of human and animal fascioliasis by Fasciola hepatica and F. gigantica. Acta Trop 111:150–159PubMedCrossRefGoogle Scholar
  173. Valero MA, Periago MV, Perez-Crespo I, Angles R, Villegas F, Aguirre C, Strauss W, Espinoza JR, Herrera P, Terashima A, Tamayo H, Engels D, Gabrielli AF, Mas-Coma S (2012a) Field evaluation of a coproantigen detection test for fascioliasis diagnosis and surveillance in human hyperendemic areas of Andean countries. PLoS Negl Trop Dis 6:e1812PubMedPubMedCentralCrossRefGoogle Scholar
  174. Valero MA, Periago MV, Perez-Crespo I, Rodríguez E, Perteguer MJ, Gárate T, González-Barberá EM, Mas-Coma S (2012b) Assessing the validity of an ELISA test for the serological diagnosis of human fascioliasis in different epidemiological situations. Trop Med Int Health 17:630–636PubMedCrossRefGoogle Scholar
  175. Valero MA, Perez-Crespo I, Khoubbane M, Artigas P, Panova M, Ortiz P, Maco V, Espinoza JR, Mas-Coma S (2012c) Fasciola hepatica phenotypic characterisation in Andean human endemic areas: valley versus altiplanic patterns analysed in liver flukes from sheep from Cajamarca and Mantaro, Peru. Infect Genet Evol 12:403–410PubMedCrossRefGoogle Scholar
  176. Valero MA, Bargues MD, Khoubbane M, Artigas P, Quesada C, Berinde L, Ubeira FM, Mezo M, Hernandez JL, Agramunt VH, Mas-Coma S (2016) Higher physiopathogenicity by Fasciola gigantica than by the genetically close F. hepatica: experimental long-term follow-up of biochemical markers. Trans R Soc Trop Med Hyg 110:55–66PubMedCrossRefGoogle Scholar
  177. Valero MA, Perez-Crespo I, Chillon-Marinas C, Khoubbane M, Quesada C, Reguera-Gomez M, Mas-Coma S, Fresno M, Gironès N (2017) Fasciola hepatica reinfection potentiates a mixed Th1/Th2/Th17/Treg response and correlates with the clinical phenotypes of anemia. PLoS One 12:e0173456PubMedPubMedCentralCrossRefGoogle Scholar
  178. Vasquez P (1943) Fasciola hepatica, Reporte del primer caso observado en Cuba, en un niño. Arch Med Intern 12:163Google Scholar
  179. Villegas F, Angles R, Barrientos R, Barrios G, Valero MA, Hamed K, Grueninger H, Ault SK, Montresor A, Engels D, Mas-Coma S, Gabrielli AF (2012) Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS Negl Trop Dis 6:e1720PubMedPubMedCentralCrossRefGoogle Scholar
  180. WHO (1995) Control of foodborne trematode infections, WHO technical report series, vol 849. World Health Organization, GenevaGoogle Scholar
  181. WHO (2007) Report of the WHO informal meeting on use of triclabendazole in fascioliasis control. World Health Organization, GenevaGoogle Scholar
  182. WHO (2008) Fact sheet on fascioliasis. In: World Health Organization (ed) Action against worms. World Health Organization, Geneva, pp 1–8Google Scholar
  183. WHO (2013) Sustaining the drive to overcome the global impact of neglected tropical diseases. World Health Organization, GenevaGoogle Scholar
  184. Winkelhagen AJ, Mank T, de Vries PJ, Soetekouw R (2012) Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands. Emerg Infect Dis 18:1028–1029PubMedPubMedCentralCrossRefGoogle Scholar
  185. Yilmaz H, Gödekmerdan A (2004) Human fasciolosis in Van province, Turkey. Acta Trop 92:161–162PubMedCrossRefGoogle Scholar
  186. Zumaquero-Ríos JL, Sarracent-Pérez J, Rojas-García R, Rojas-Rivero L, Martínez-Tovilla Y, Valero MA, Mas-Coma S (2013) Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla state, Mexico: epidemiology and treatment with nitazoxanide. PLoS Negl Trop Dis 7:e2553PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Santiago Mas-Coma
    • 1
    Email author
  • Mª Adela Valero
    • 1
  • Mª Dolores Bargues
    • 1
  1. 1.Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de FarmaciaUniversidad de ValenciaValenciaSpain

Personalised recommendations